<PAGE>
                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

                    QUARTERLY REPORT FOR THE QUARTERLY PERIOD
                            ENDED SEPTEMBER 30, 2004

                           COMMISSION FILE NO. 0-28077

                                 GENELINK, INC.
                 ----------------------------------------------
                 (Name of Small Business Issuer in its charter)

               PENNSYLVANIA                           23-2795613
               ------------                           -------------
        (State or other jurisdiction of     (I.R.S. Employer Identification No.)
        incorporation or organization)


           100 S. Thurlow Street
          Margate, New Jersey                            08402
     --------------------------------------             --------
    (Address of principal executive offices)           (Zip Code)

                    ISSUER'S TELEPHONE NUMBER: (609) 823-6991


      Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X]  No [ ]

      APPLICABLE ONLY TO CORPORATE ISSUERS: Indicate the number of shares
outstanding of each of the issuer's classes of common stock, as of the latest
practicable date.

            Number of Shares of Common Stock
              Outstanding on November 1, 2004             30,940,329

      Transitional Small Business Disclosure Format   Yes [ ]   No  [X]
<PAGE>
                                 GENELINK, INC.

<TABLE>
<S>         <C>                                                                    <C>
PART I.     FINANCIAL INFORMATION

ITEM 1.     Financial Statements.

            Balance Sheets at September 30, 2004 (unaudited) and December 31, 2003   3

            Statements of Operations for the three months and nine months ended
              September 30, 2004 and 2003 (unaudited)                               4-5

            Statements of Cash Flows for the nine months ended September 30, 2004
              and 2003 (unaudited)                                                  6-7

            Notes to Financial Statements                                           8-10

</TABLE>

                                       2
<PAGE>
                                 GENELINK, INC.
                                 BALANCE SHEETS
<TABLE>
<CAPTION>
                                                   (UNAUDITED)
                                               SEPTEMBER 30, 2004     DECEMBER 31, 2003
                                               ------------------     -----------------
<S>                                                <C>                  <C>
ASSETS
Cash                                               $     2,933          $   746,082
Accounts receivable                                    173,643               43,556
Inventory                                               21,230               20,041
Prepaid expenses                                        88,995              197,221
                                                   -----------          -----------
      Total current assets                             286,801            1,006,900

Property and equipment                                  97,347               70,435
Other assets                                           183,317              134,485
                                                   -----------          -----------
                                                   $   567,465          $ 1,211,820
                                                   ===========          ===========
LIABILITIES

Accounts payable and accrued expenses              $   131,550          $    46,966
Accrued payroll taxes                                   15,265               55,094
                                                   -----------          -----------
      Total current liabilities                        146,815              102,060

Accrued compensation                                   433,779              336,306
Loans payable                                          143,691               33,000
                                                   -----------          -----------
                                                       724,285              471,366
                                                   -----------          -----------
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, $.01 par value,
  75,000,000 shares authorized
  31,271,999 and 31,005,011 shares
  issued, 30,865,829 and 30,808,831
  outstanding as of September 30,
  2004 and December 31, 2003, respectively             312,720              310,050
Treasury stock, 406,170 and196,180 shares
  as of September 30, 2004 and
  December 31, 2003, respectively                     (315,055)            (205,860)
Additional paid-in capital                           6,579,407            6,774,021
Stock subscriptions receivable                               0           (1,016,635)
Stock warrants                                       2,272,422            2,247,802
Accumulated deficit                                 (9,006,314)          (7,368,924)
                                                   -----------          -----------
                                                      (156,820)            (740,454)
                                                   -----------          -----------
                                                   $   567,465          $ 1,211,820
                                                   ===========          ===========
</TABLE>

     The accompanying notes are an integral part of the financial statements

                                       3
<PAGE>
                                 GENELINK, INC.
                            STATEMENTS OF OPERATIONS
                                   (UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS ENDED SEPTEMBER 30,                     2004             2003
                                                 -----------      -----------
<S>                                              <C>              <C>
REVENUE                                          $   157,054      $    22,717
COST OF GOODS SOLD                                    15,871            8,949
                                                 -----------      -----------
GROSS PROFIT                                         141,183           13,768
                                                 -----------      -----------
EXPENSES
      Selling, general and administrative            178,514          157,429
      Consulting                                      85,716           43,565
      Professional fees                               25,230           47,466
      Advertising and promotion                       24,472            7,898
      Amortization and depreciation                    6,359            5,059
                                                 -----------      -----------
                                                     320,291          261,417
                                                 -----------      -----------
NET LOSS BEFORE EXTRAORDINARY ITEM                  (179,108)        (247,649)

EXTRAORDINARY ITEM - WRITE-OFF OF
  ADVANCES TO RELATED PARTY                                0            7,889
                                                 -----------      -----------
NET LOSS BEFORE PROVISION FOR
  INCOME TAXES                                      (179,108)        (255,538)

PROVISIONS FOR INCOME TAXES                                0                0
                                                 -----------      -----------
NET LOSS                                         $  (179,108)     $  (255,538)
                                                 ===========      ===========
NET LOSS PER SHARE BASIC AND DILUTED             $     (0.01)     $     (0.01)
                                                 ===========      ===========
Weighted average common shares and
  diluted potential common shares                 31,208,466       26,288,644
                                                 ===========      ===========
</TABLE>

   The accompanying notes are an integral part of the financial statements.


                                       4
<PAGE>
                                 GENELINK, INC.
                            STATEMENTS OF OPERATIONS
                                   (UNAUDITED)
<TABLE>
<CAPTION>

NINE MONTHS ENDED SEPTEMBER 30,                      2004              2003
                                                 ------------      ------------
<S>                                              <C>               <C>
REVENUE                                          $    254,705      $     65,753
COST OF GOODS SOLD                                     70,847            36,269
                                                 ------------      ------------
GROSS PROFIT                                          183,858            29,484
                                                 ------------      ------------
EXPENSES
      Selling, general and administrative           1,283,823           562,680
      Consulting                                      284,482           153,229
      Professional fees                               173,800           301,433
      Advertising and promotion                        61,001            33,184
      Amortization and depreciation                    18,142            13,771
                                                 ------------      ------------
                                                    1,821,248         1,064,297
                                                 ------------      ------------
NET LOSS BEFORE EXTRAORDINARY
  ITEM                                             (1,637,390)       (1,034,813)

EXTRAORDINARY ITEM- WRITE-OFF OF
  ADVANCE TO RELATED PARTY                                  0           137,741
                                                 ------------      ------------
NET LOSS BEFORE PROVISION FOR
  INCOME TAXES                                     (1,637,390)       (1,172,554)

PROVISION FOR INCOME TAXES                                  0                 0
                                                 ------------      ------------
NET LOSS                                         $ (1,637,390)     $ (1,172,554)
                                                 ============      ============
NET LOSS PER SHARE BASIC AND DILUTED             $      (0.05)     $      (0.06)
                                                 ============      ============
Weighted average common shares and
  diluted potential common shares                  31,094,099        21,503,048
                                                 ============      ============

</TABLE>

    The accompanying notes are an integral part of the financial statements.

                                       5
<PAGE>
                                 GENELINK, INC.
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)
<TABLE>
<CAPTION>

NINE MONTHS ENDED SEPTEMBER 30,                               2004             2003
                                                          -----------      -----------
<S>                                                       <C>              <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss                                                  $(1,637,390)     $(1,172,554)
Adjustments to reconcile net loss to net
  cash used by operating activities
Depreciation and amortization                                  18,142           13,771
Fair value of compensation related to vested options           21,747                0
Common stock issued for services                              145,640          828,856
Common stock issued to related party                                0           20,000
Fair value of options granted for services                     19,750           55,700
Changes in operating assets and liabilities
  Accounts receivable                                        (130,087)         (31,243)
  Inventory                                                    (1,189)           4,406
  Prepaid expenses                                            108,226           11,025
  Deposits                                                     (8,750)               0
  Accounts payable and accrued expenses                        84,584           47,108
  Accrued payroll taxes                                       (39,829)          32,216
  Deferred revenue                                                  0           14,985
  Accrued compensation                                        194,392          (18,186)
                                                          -----------      -----------
Net cash used by operating activities                      (1,224,764)        (193,916)
                                                          -----------      -----------
CASH FLOWS FROM INVESTING ACTIVITIES
  Advance to officer                                                0          (31,587)
  Capital expenditures                                        (35,816)         (29,345)
  Advance to related party                                    (49,319)               0
                                                          -----------      -----------
Net cash used by investing activities                         (85,135)         (60,932)
                                                          -----------      -----------
CASH FLOWS FROM FINANCING ACTIVITIES
  Contribution of services by officer                         448,000                0
  Reduction of paid in capital                                      0         (448,000)
  Proceeds relating to issuance of common stock (net)               0          759,500
  Proceeds from note payable                                  121,943                0
  Proceeds from issuance of warrants                           53,057                0
  Repayment of loans payable                                  (33,000)         (10,000)
  Common stock issued for fundraising                         (23,250)               0
                                                          -----------      -----------
Net cash provided by financing activities                     566,750          301,500
                                                          -----------      -----------
</TABLE>

    The accompanying notes are an integral part of the financial statements.

                                       6
<PAGE>
                                 GENELINK, INC.
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)
<TABLE>
<CAPTION>
NINE MONTHS ENDED SEPTEMBER 30,                        2004          2003
                                                   -----------      --------
<S>                                                   <C>             <C>
NET INCREASE (DECREASE) IN CASH AND
  CASH EQUIVALENTS                                    (743,149)       46,652

Cash and cash equivalents, beginning of period         746,082        31,203
                                                   -----------      --------
Cash and cash equivalents, end of period           $     2,933      $ 77,855
                                                   -----------      --------
SUPPLEMENTARY CASH FLOW INFORMATION
  Income taxes paid                                          0             0
  Interest paid                                              0             0

NON-CASH FINANCING TRANSACTIONS
  Accrued interest on subscriptions receivable          12,300        33,886
  Issuance of common stock for services                145,640       828,856
  Accrued interest on advance to related party               0        21,024
  Issuance of common stock to related party                  0        20,000
  Reduction of paid in capital                         779,271             0
  Repayment of subscription receivable               1,028,934             0
  Purchase of treasury stock                           109,195             0
  Stock option granted for services                     19,750        45,500
  Payment of accrued compensation                       96,919             0

</TABLE>

    The accompanying notes are an integral part of the financial statements.

                                       7
<PAGE>
                                                                  GENELINK, INC.
                                           NOTES TO INTERIM FINANCIAL STATEMENTS
================================================================================

1. DESCRIPTION OF    BUSINESS ORGANIZATION
   ORGANIZATION      GeneLink, Inc. (the Company), operating in New Jersey, was
                     organized under the laws of the Commonwealth of
                     Pennsylvania. The Company is the successor to a Delaware
                     Corporation organized under the same name on September 21,
                     1994. The Company's offices are located in Margate, New
                     Jersey.

                     BUSINESS DESCRIPTION
                     The Company was founded in response to the information
                     being generated in the field of human molecular genetics.
                     Management believes future generations could benefit from
                     the DNA store of knowledge, as scientists are discovering
                     an increasing number of connections between genes and
                     specific diseases. For this reason, the Company has created
                     a DNA banking service that stores DNA before and after an
                     individual dies. This genetic history can help families
                     determine if they are at risk for certain inherited
                     diseases. DNA banking shifts the emphasis from diagnosis
                     and treatment to detection and prevention.

                     The Company has developed a patented DNA Collection Kit for
                     the collection of DNA specimens of its clients. The DNA
                     will be stored for 75-year intervals. Upon a client's
                     request, and upon the payment of a retrieval fee, the
                     stored DNA specimen can be retrieved and sent to a
                     laboratory for testing.

                     The Company has created proprietary methodology for SNP
                     (single nucleotide polymorphism) based on nutragenetic(R)
                     and dermagenetic(R) profiling. These profiles (patents
                     pending) provide a means of predicting an individual's
                     inherent genetic capacity to combat oxidative stress and
                     other important selected areas of physiological health.
                     These profile assessments enable nutritional and skin care
                     companies to recommend a specific and targeted regime of
                     antioxidant vitamins, nutrients or skin care formulations
                     that have been specifically designed to compensate for
                     predicted deficiencies. The Company's patented DNA
                     Collection Kit will be used for these assessments.

                                       8
<PAGE>
                                                                  GENELINK, INC.
                                           NOTES TO INTERIM FINANCIAL STATEMENTS
================================================================================

2. BASIS OF          The accompanying unaudited financial statements have been
   PRESENTATION      prepared by the Company in accordance with the instructions
                     to Form 10-Q and Article 10 of Regulation S-X relating to
                     interim financial statements. Accordingly, they do not
                     include all of the information and footnotes required by
                     generally accepted accounting principles for complete
                     financial statements and should be read in conjunction with
                     the financial statements and notes thereto included in the
                     Annual Report on Form 10-KSB of GeneLink, Inc. for the year
                     ended December 31, 2003.

                     In the opinion of management, all adjustments (consisting
                     of normal recurring accruals) necessary to present fairly
                     the information set forth in the accompanying financial
                     statements have been included. The results reported in
                     these financial statements for the nine-month period ended
                     September 30, 2004 should not be regarded as necessarily
                     indicative of results that may be expected for the year
                     ended December 31, 2004.

3. SHAREHOLDERS'
   EQUITY
   TRANSACTIONS      A. COMMON STOCK
                     The Company issued 267,000 shares of common stock for
                     services rendered, valued at $145,640 for the nine months
                     ended September 30, 2004.

                     B. STOCK OPTIONS AND WARRANTS
                     During the nine months ended September 30, 2004 the Company
                     issued 55,000 options to purchase common stock for
                     consulting services, valued at $19,750.

4 - NOTE PAYABLE     During the nine months ended September 30, 2004, various
                     shareholders loaned the Company $175,000. The notes mature
                     between December 16, 2004 and July 28, 2005, with interest
                     accruing at 6% per annum. In connection with the notes, the
                     Company granted 350,000 warrants with an exercise price of
                     $.25 per share. The total funds received of $175,000 were
                     allocated $53,057 to the warrants and $121,943 to the
                     notes. The fair value of the warrants of $77,500 at the
                     time of issuance, which was determined using the
                     Black-Scholes option-pricing model, were recorded as
                     additional-paid-in-capital and reduced the carrying value
                     of the notes. The discount on the notes are being amortized
                     in interest expense over the term of the notes.

5. TRANSACTIONS
   WITH RELATED
   PARTIES           On June 29, 2003, the Company issued to John DePhillipo
                     2,722,345 shares and Maria DePhillipo 723,530 shares in
                     satisfaction of accrued and unpaid salary of $544,469 owed
                     to John


                                       9
<PAGE>
                                                                  GENELINK, INC.
                                           NOTES TO INTERIM FINANCIAL STATEMENTS
================================================================================


                     DePhillipo and $144,704 owed to Maria DePhillipo. Effective
                     March 24, 2004, the Board of Directors of the Company
                     decided to provide additional compensation payable to John
                     DePhillipo and Maria DePhillipo to reflect the desire of
                     the Board to treat the shares issued June 29, 2003 to John
                     Dephillipo not as issuances in satisfaction of accrued and
                     unpaid salary, but as additional compensation. To reflect
                     the additional compensation granted, the Company recorded
                     $544,469 of additional compensation to John DePhillipo
                     during March 2004.

                     On April 13, 2004, John DePhillipo repaid his advances from
                     the Company of $1,028,934. Of that amount, interest accrued
                     of $331,271 on the advances was forgiven by the Company.
                     Additional, compensation of $544,919 owed to John
                     DePhillipo, and $43,550 owed Maria DePhillipo was offset
                     against the advances. John DePhillipo transferred 209,990
                     shares valued at $.52 per share in repayment of the
                     $109,195 remaining.


                                       10
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

Statements in this Report that relate to future results and events are based on
the Company's current expectations. Actual results in future periods may differ
materially from those currently expected or desired because of a number of risks
and uncertainties. For a discussion of factors affecting the Company's business
and prospects, see "Item 2 - Management's Discussion and Analysis of Financial
Condition and Results of Operations - Factors Affecting the Company's Business
and Prospects."

Operating results for the nine-month period ended September 30, 2004 are not
necessarily indicative of the results that may be expected for the full fiscal
year ending December 31, 2004.

LIQUIDITY AND CAPITAL RESOURCES

For the nine month period ended September 30, 2004, the Company's primary
liquidity requirements have been research and development, funding of its sales
and marketing efforts, the payment of compensation to officers and other
employees and the payment of accounts payable. In the first nine months of 2004,
the Company raised $175,000, through the issuance of notes and warrants.

Cash and cash equivalents at September 30, 2004 amounted to $2,933 as compared
to $746,082 at December 31, 2003, a decrease of $743,149. During the first nine
months of 2004, the Company's operating activities utilized $1,224,764, as
compared to $193,916 for the first nine months of 2003. Cash utilized during the
nine months period ended September 30, 2004 primarily was used to fund a portion
of the Company's $1,637,390 net losses for such period.

Financing activities provided $566,750 for the nine month period ended September
30, 2004 as compared to $301,500 for the nine months ended September 30, 2003.
Financing activities in the nine months ended September 30, 2004 resulted
primarily from the issuance of $175,000 of notes and warrants throughout the
first nine months of 2004 and the contribution of services by an officer of the
Company valued at $448,000.

The Company will require approximately $1,000,000 for research and development,
for working capital and to pay accounts payable. The Company intends to raise
funds through the private placement of its securities. Unless the Company can
increase its revenues and increase its stock price, it is unlikely that the
Company will be able to secure such financing. If the Company is not able to
secure such additional required capital, it will continue to realize negative
cash flow and losses and may not be able to continue operations.

                                       11
<PAGE>
        COMPARISON OF THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2003
             TO THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2002

FINANCIAL CONDITION

Assets of the Company decreased from $1,211,820 at December 31, 2003 to $567,465
at September 30, 2004, a decrease of $644,355. This decrease was primarily due
to a decrease in cash from $746,082 at December 31, 2003 to $2,933 at September
30, 2004, a decrease of $743,149, which was principally used to fund working
capital expenses and net losses. The decrease in cash was partially effect by an
increase in accounts receivable from $43,556 at December 31, 2003 to $173,643 at
September 30, 2004, an increase of $130,087, as the Company continued to
increase its revenues from sale of products.

Liabilities increased from $471,366 at December 31, 2003 to $724,285 at
September 30, 2004, an increase of $252,919. This increase in liabilities
primarily resulted due to an increase in accounts payable and accrued expenses
from $46,966 at December 31, 2003 to $131,550 at September 30, 2004, an increase
of $84,584, and an increase in loans payable from $33,000 at December 31, 2003
to $143,691, at September 30, 2004, an increase of $110,691.

CURRENT YEAR PERFORMANCE AND EARNINGS OUTLOOK

Revenues. The total revenues for the nine months ended September 30, 2004 were
$254,705 as compared to $65,753 for the nine months ended September 30, 2003, an
increase of $188,952, or 287%. Total revenues for the three months ended
September 30, 2004 were $157,054 as compared to $22,717 for the three months
ended September 30, 2003, an increase of $134,377, or 591%.

Expenses. Total expenses before extraordinary items for the nine months ended
September 30, 2004 were $1,821,248 as compared to $1,064,297 for the nine months
ended September 30, 2003, an increase of $756,951, primarily resulting from an
increase in selling, general and administrative expenses from $562,680 for the
nine months ended September 30, 2003 to $1,283,823 for the nine months ended
September 30, 2004, an increase of $721,143, principally relating to a one time
stock bonus of $544,469 to an officer of the Company. Total expenses for the
three months ended September 30, 2004 were $320,291, as compared to $261,417 for
the three months ended September 30, 2003, an increase of $58,874, primarily
resulting from an increase in consulting fees from $43,565 for the three months
ended September 30, 2003 to $85,716 for the three months ended September 30,
2004, an increase of $42,151.

Losses. The Company incurred a loss before extraordinary items of $1,637,390 for
the nine months ended September 30, 2004 as compared to a loss of $1,172,554 for
the nine months ended September 30, 2003, an increase of $464,836, primarily
resulting from the increase in expenses for the nine months ended September 30,
2004 of $756,951, as partially offset by an $188,952 increase in revenues for
the nine months ended September 30, 2004, compared to nine months ended
September 30, 2003.

                                       12
<PAGE>
The Company incurred a loss of $179,108 for the three months ended September 30,
2004, as compared to a loss of $247,649 for the three months ended September 30,
2003, a decrease of $68,541, primarily resulting from an increase in revenues
for the three months ended September 30, 2004 of $134,337, as partially offset
by a $58,874 increase in expenses the three months ended September 30, 2004,
compared to the three months ended September 30, 2003.

FACTORS AFFECTING THE COMPANY'S BUSINESS AND PROSPECTS

There are a number of factors that affect the Company's business and the results
of its operations. These factors include general economic and business
conditions; the level of acceptance of the Company's products and services; the
rate and commercial applicability of advancements and discoveries in the
genetics field; the Company's ability to enter into strategic alliances with
companies in the nutragenetics and dermagenetics industries; and the ability of
the Company to raise the financing necessary to implement its business and
marketing plan, to pay salaries to its officers and employees and to pay its
accounts payable.

ITEM 3. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

The Company maintains disclosure controls and procedures that are designed to
ensure that information required to be disclosed in its Exchange Act reports is
recorded, processed, summarized and reported within the time periods specified
in the Securities and Exchange Commission's rules and forms, and that such
information is accumulated and communicated to management, including the Chief
Executive Officer and Chief Financial Officer, as appropriate, to allow timely
decisions regarding required disclosure. Management necessarily applies its
judgment in assessing the costs and benefits of such controls and procedures,
which, by their nature, can provide only reasonable assurance regarding
management's control objectives.

With the participation of management, the Company's Chief Executive Officer and
Chief Financial Officer evaluated the effectiveness of the design and operation
of the Company's disclosure controls and procedures at the conclusion of the
three months ended September 30, 2004. Based upon this evaluation, the Chief
Executive Officer and Chief Financial Officer concluded that the Company's
disclosure controls and procedures were effective in ensuring that material
information required to be disclosed is included in the reports that it files
with the Securities and Exchange Commission.

CHANGES IN INTERNAL CONTROLS

There were no significant changes in the Company's internal controls or, to the
knowledge of management of the Company, in other factors that could
significantly affect internal controls subsequent to the date of the Company's
most recent evaluation of its disclosure controls and procedures utilized to
compile information included in this filing.

                                       13
<PAGE>
PART II.    OTHER INFORMATION

ITEM 6.     Exhibits and Reports on Form 8-K.

            (a)   Exhibit No.

                  31.1 Certification of Chief Executive Officer and Chief
                  Financial Officer pursuant to Section 302 of the
                  Sarbanes-Oxley Act of 2002

                  32.1 Certification pursuant to 18 U.S.C. Section 1350, as
                  adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
                  2002.

            (b)   Reports on Form 8-K.

                  No reports on Form 8-K were filed during the quarter for which
                  this report is filed.

                                   * * * * * *

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                        GENELINK, INC.
                                        (Registrant)


Date: November 11, 2004                 By: /s/ John R. DePhillipo
                                            -----------------------------------
                                            John R. DePhillipo, Chief Executive
                                             Officer and Chief Financial Officer

                                       14